The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) – ...

A much touted emerging treatment, red light therapy, lives up to the hype for a lot of health claims, but certainly not ...

"The laser beam can be positioned with great accuracy on surfaces, so we can produce significantly smaller microlenses than is possible with previously existing methods," commented Thomas Höche head ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price lowered by equities researchers at Bernstein Bank from $1,070.00 to $1,000.00 in a research note issued to investors on ...

Microlenses applied to eyeglasses can help reduce growth-related worsening of nearsightedness (myopia), preventing potential ...

Background: Myopia is one of the most common eye diseases leading to blurred distance vision. Inflammatory diseases could trigger or exacerbate myopic changes. Although gut microbiota bacteria are ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by equities research analysts at Leerink Partners from $980.00 to $862.00 in a research note issued on Tuesday.

The World Health Organization reports that around 2.2 billion people struggle with vision problems such as near-sightedness ...

16, 2025 — A new report shows the benefit of wearing contact lenses for slowing myopia has a lasting ... 14, 2025 — Age-related macular degeneration (AMD), which affects about 200 million ...